Pathologies Associated with the p53 Response
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Although p53 is a major cancer preventive factor, under certain extreme stress conditions it may induce severe pathologies. Analyses of animal models indicate that p53 is largely responsible for the toxicity of ionizing radiation or DNA damaging drugs contributing to hematopoietic component of acute radiation syndrome and largely determining severe adverse effects of cancer treatment. p53-mediated damage is strictly tissue specific and occurs in tissues prone to p53-dependent apoptosis (e.g., hematopoietic system and hair follicles); on the contrary, p53 can serve as a survival factor in tissues that respond to p53 activation by cell cycle arrest (e.g., endothelium of small intestine). There are multiple experimental indications that p53 contributes to pathogenicity of acute ischemic diseases. Temporary reversible suppression of p53 by small molecules can be an effective and safe approach to reduce severity of p53-associated pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“This has led the p53 field to predominantly focus on the possibility of restoring p53 activity as a way to induce cancer cell death (Hupp et al. 1995; Bottger et al. 1997; Selivanova et al. 1997; Foster et al. 1999; Midgley et al. 2000; Bykov et al. 2002; Issaeva et al. 2004; Vassilev et al. 2004).”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 3×
“Three papers (Martins et al. 2006; Ventura et al. 2007; Xue et al. 2007) reported that restoration of p53 function in established tumors (including lymphomas, sarcomas, and hepatocellular carcinomas) caused regression of the tumors in vivo and could, therefore, represent an effective approach to…”
BackgroundTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 8×
“The validity of this approach is supported by numerous demonstrations of the antitumor effect of p53 activated either by genetic manipulation (Ventura et al. 2007; Xue et al. 2007) or by small molecules (Selivanova et al. 1997; Vassilev 2005; Kravchenko et al. 2008) including drugs that inhibit the…”
BackgroundInfluentialp53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 1×
“Also, several knockout and transgenic mouse lines that showed increased p53 activity had premature aging phenotypes (Chin et al. 1999; Lim et al. 2000; Tyner et al. 2002; Cao et al. 2003; Wong et al. 2003; Varela et al. 2005).”
BackgroundA Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Self-citationRegulation of autophagy by cytoplasmic p53
Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1730 · Cited by 1,132
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“This has led the p53 field to predominantly focus on the possibility of restoring p53 activity as a way to induce cancer cell death (Hupp et al. 1995; Bottger et al. 1997; Selivanova et al. 1997; Foster et al. 1999; Midgley et al. 2000; Bykov et al. 2002; Issaeva et al. 2004; Vassilev et al. 2004).”
BackgroundChin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979 · cited 2×
“Also, several knockout and transgenic mouse lines that showed increased p53 activity had premature aging phenotypes (Chin et al. 1999; Lim et al. 2000; Tyner et al. 2002; Cao et al. 2003; Wong et al. 2003; Varela et al. 2005).”
Background
Cited by
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis
Vaseva, A. V., Marchenko, N. D., Ji, K., Tsirka, S. E., Holzmann, S., & Moll, U. M. (2012) · Cell · doi:10.1016/j.cell.2012.05.014 · Cited by 740
“Since both p53 and mPT play important roles during oxidative stress (Gudkov and Komarova, 2010; Halestrap, 2006; Vaseva and Moll, 2009), we looked for an interaction between p53 and the PTP components CypD, ANT, and VDAC upon H2O2 treatment.”
BackgroundRole of p53 in the Regulation of Cellular Senescence
Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F., & Giordano, A. (2020) · Biomolecules · doi:10.3390/biom10030420 · Cited by 639
“In this context, tissue specific differences can influence different p53 expression, contributing to the determination of the cell fate after exposure to genotoxic stress [74].”
BackgroundUnderstanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“, 2017) have been described, while p53 can also contribute to non-cancer pathologies such as neurodegenerative disease and ischaemia (Gudkov and Komarova, 2010).”
BackgroundCeccaldi, R., Parmar, K., Mouly, E., Delord, M., Kim, J. M., Regairaz, M., Pla, M., Vasquez, N., Zhang, Q.-S., Pondarre, C., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.013 · Cited by 340
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129
Thielmann, M., Corteville, D., Szabo, G., Swaminathan, M., Lamy, A., Lehner, L. J., Brown, C. D., Noiseux, N., Atta, M. G., Squiers, E. C., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.053029 · Cited by 97
Metadata
- Authors
- Gudkov, A. V., & Komarova, E. A.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2010-04-07
- Volume
- 2
- Issue
- 7
- Pages
- a001180-a001180
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2113880766
- Cited by
- 115
- References
- 25
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.